INODESIA DIABETES CARE DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

INODESIA DIABETES CARE DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Indonesia Diabetes Care Drugs Market is expected to register a CAGR greater than 4% over the forecast period, 2022-2027.

The coronavirus disease 2019 (COVID-19) pandemic is a catastrophic global public health crisis caused by the SARS coronavirus 2 (SARS-CoV-2) virus. COVID-19 has a broad clinical spectrum, with symptoms ranging from asymptomatic to severe illness, including fever and potentially lethal pneumonia in patients with comorbidities. The COVID-19 pandemic begins in 2020, while the effort to develop a responsive diabetes care healthcare system continues. As of May 2021, 1.7 million individuals had been infected with SARS CoV-2, with 2.76% of cases (47,976 people) dying. As a result, according to COVID-19, Indonesia was the worst-affected country in Southeast Asia. These occurrences have a significant influence on people with disabilities. Diabetes people are more likely to become very ill if they contract the virus.

In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and there are only a few insulin manufacturers on the market. As a result, there is fierce rivalry among these producers, who are continually striving to satisfy the demands of patients by providing the highest-quality insulin.

Key Market TrendsOral-Anti Diabetes Drugs Segment is Having the Highest Market Share in 2021

The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 4 % during the forecast period, mainly due to the demand from the Type-1 diabetes population, which was more than 12 million by the end of 2022.

Indonesia’s struggle to develop a responsive healthcare system is exacerbated by an environment where health insurance coverage is incomplete. The Government aims to achieve universal health coverage. Askeskin/Jamkesmas, the national health insurance system for the poor or almost poor, is the largest government health insurance program. Askes offers health insurance to public officials and retired army personnel. Jamsostek covers formal sector workers. Meanwhile, around 3% of the population has private health insurance.

Diabetes education programs are provided by healthcare providers in Indonesia. In Indonesia, the availability of certified diabetic educators is restricted, resulting in a scarcity of qualified health care professionals (HCPs) to educate persons with diabetes. In the Indonesian setting, there is limited data regarding how people with diabetes learn about their disease after receiving diabetes-related information informally or officially through organized educational programs.

Increasing Diabetes Population in Indonesia

Diabetes in Indonesia is considered a major health problem and has been a concern. Diabetes specialists have created recommendations for preventing and controlling diabetes to address the growing number of diabetics in Indonesia. Diabetes management is critical to preventing serious consequences such as neuropathy, nephropathy, retinopathy, microvascular disease, and cardiovascular disease. Pharmacologic therapy such as oral medicines and insulin, as well as non-pharmacologic therapies such as lifestyle changes, are still considered modern approaches for diabetes management. These therapies are only possible through diabetes teaching programs that promote self-care management. Diabetes education programs are provided by healthcare providers in Indonesia. In Indonesia, the availability of certified diabetic educators is restricted, resulting in a scarcity of qualified health care professionals (HCPs) to educate persons with diabetes.

In terms of the number of diabetics, Indonesia ranks seventh in the world. In Indonesia, people's health is primarily covered by national government insurance. Government insurance covers medical requirements such as consultation, hospitalization, insulin, and needles through designated clinics or hospitals and licensed pharmacies. However, due to a lack of knowledge and information on type 1 diabetes, a misunderstanding occurred, resulting in insulin access limits. The amount of insulin made available through government insurance was limited. For example, a child with type 1 diabetes who is supposed to receive eight insulin pens per month was only given five insulin pens per month, requiring the parents to purchase the remaining three pens at their own expense, and if they did not have the money, they were unable to meet their child's insulin needs.

Thus, owing to the above factors it is expected to drive the market growth over the forecast period.

Competitive Landscape

The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.